Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Treanda, Bendeka
Bendamustine is an alkylating antineoplastic agent used in the treatment of certain types of cancers. It belongs to the nitrogen mustard class of chemotherapeutic drugs and is unique in its bifunctional structure, combining features of both alkylating agents and purine analogs. Bendamustine interferes with DNA replication and repair, ultimately leading to cell death. It is often used in patients who have not responded well to other treatments.
For the treatment of chronic lymphocytic leukemia (CLL), indolent B-cell non-Hodgkin lymphoma (NHL), and multiple myeloma.
Bendamustine can cause myelosuppression, including prolonged cytopenias, which can be life-threatening. Secondary malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have also been reported.
Outcome:
Increased risk of bone marrow suppression
Mechanism:
Additive myelosuppression
Outcome:
Increased risk of bleeding
Mechanism:
Additive effects on platelet function
Outcome:
Reduced absorption of bendamustine
Mechanism:
Antacids may bind to bendamustine
Most likely new formulation: Liposomal bendamustine for improved efficacy and reduced toxicity (2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of bendamustine expanding indications to other hematological malignancies in the next 5 years.
Alkylating agent, Antineoplastic
Nitrogen mustard